The IRMA Community
Newsletters
Research IRM
Click a keyword to search titles using our InfoSci-OnDemand powered search:
|
CRISPR-Cas9 Technology for Epigenome Editing in Precision Medicine: Opportunities and Challenges
|
|
Author(s): M. M. Nidhilangelo (Pondicherry University, India)and Ranjith Kumavath (Pondicherry University, India)
Copyright: 2026
Pages: 36
Source title:
CRISPR-Cas9 Technology for Precision Medicine
Source Author(s)/Editor(s): Jen-Tsung Chen (National University of Kaohsiung, Taiwan)
DOI: 10.4018/979-8-3373-4857-5.ch009
Purchase
|
Abstract
CRISPR–Cas9, originally derived from a bacterial adaptive immune system, has rapidly evolved into a transformative platform for genome and epigenome engineering with broad applications in biology and precision medicine. Guided by single-guide RNAs, the Cas9 nuclease introduces targeted DNA modifications through cellular repair pathways. Meanwhile, engineered variants, such as high-fidelity nucleases, nickases, and nuclease-deficient dCas9, extend their functionality to precise gene regulation, epigenetic modulation, RNA editing, and live-cell genomic imaging. dCas9-based effectors enable locus-specific control of transcription by directing DNA methylation, histone modifications, or chromatin remodelling, offering reversible and non-permanent alternatives to conventional epigenetic drugs. In vivo models, including somatically engineered mouse models and xenografts, enable physiologically relevant studies of tumorigenesis and therapeutic response, while base and prime editors offer safer, DNA break–free approaches for the precision correction of pathogenic variants. Clinically, CRISPR is driving innovation in adoptive immunotherapies, regenerative medicine, and targeted delivery systems, with nanoparticle- and ligand-modified carriers improving tissue-specific targeting and reducing systemic toxicity. Despite these advances, major challenges remain, including off-target activity, inefficient and tissue-restricted delivery, instability of epigenetic edits, and ethical concerns surrounding germline modification and long-term safety. Ongoing innovations in CRISPR engineering, delivery technologies, and regulatory oversight are addressing these barriers. Collectively, CRISPR-based platforms represent a cornerstone of next-generation personalised therapeutics, offering programmable, scalable, and clinically relevant strategies to understand and treat human disease.
Related Content
|
Kazi Asraf Ali, Rideb Chakraborty, Naureen Afrose, Chowdhury Mobaswar Hossain, Amit Kotal, Sourav Samanta.
© 2026.
34 pages.
|
|
V. N. Pallavi, Savitha Chowdareddy, Bhumika Iranna Byalahunasishetter, Ramya Raghavan.
© 2026.
38 pages.
|
|
M. Suriya, V. Aarthi, S. S. Meenambiga, P. Prakash, P. Vivek.
© 2026.
34 pages.
|
|
Kumar Ebenezar Kesavarao, Manoj Mani, Mokesh Kadhirvel, Balaji Esakkimuthu, Akilandeswari Govindraj, Jerline Babu Maria, Velayuthaprabhu Shanmugam, Vijaya Anand Arumugam.
© 2026.
40 pages.
|
|
Ajay Sharma, Pratibha Singh.
© 2026.
28 pages.
|
|
Arthi Gunasekaran, Muthupandi Vanaraj, Maria Sneha Philip Kumar, Abidharini Jothi Dheivasikamani, Arthi Boro, Antony Prabhu Jeyabal Philomenathan, Alwin Robert Asirvatham, Vijaya Anand Arumugam.
© 2026.
34 pages.
|
|
Saloua Mabsor-Zgandaoui, Khawla Rachmoune, Soumia Ed-Day.
© 2026.
30 pages.
|
|
|